Literature DB >> 10208589

Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra.

K Parain1, M G Murer, Q Yan, B Faucheux, Y Agid, E Hirsch, R Raisman-Vozari.   

Abstract

Several in vitro and in vivo studies have shown that brain-derived neurotrophic factor (BDNF) promotes survival of damaged mesencephalic dopaminergic neurons. Using a specific antibody directed against human recombinant BDNF, we studied the expression of the protein at the cellular level in the post-mortem mesencephalon of control subjects and patients with Parkinson's disease (PD). In control subjects, BDNF was expressed in all mesencephalic regions containing dopaminergic neurons, and in the substantia nigra pars compacta (SNpc) 65% of the melanized neurons expressed BDNF. In the PD SNpc, the total number of pigmented neurons containing BDNF was reduced to 9.6% of the corresponding control value. In contrast, the number of pigmented neurons non-immunoreactive for BDNF was reduced to 23.9% of the corresponding control value. This result appears to indicate that SNpc melanized neurons not expressing BDNF have a 2.5-fold greater probability of surviving than BDNF-positive melanized neurons. Furthermore, we found that in parkinsonian mesencephalon almost all dopaminergic neurons containing Lewy bodies were immunoreactive for BDNF. These findings demonstrate a reduced expression of BDNF in PD and suggest that BDNF protein expression does not protect melanized SNpc neurons from the degenerative process in this disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208589     DOI: 10.1097/00001756-199902250-00021

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  76 in total

1.  Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration.

Authors:  Maryna Baydyuk; Madeline T Nguyen; Baoji Xu
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

Review 2.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

3.  Role of Apolipoprotein E, Cathepsin D, and Brain-Derived Neurotrophic Factor in Parkinson's Disease: A Study from Eastern India.

Authors:  Prosenjit Pal; Tamal Sadhukhan; Subhadip Chakraborty; Sriparna Sadhukhan; Arindam Biswas; Shyamal K Das; Kunal Ray; Jharna Ray
Journal:  Neuromolecular Med       Date:  2019-05-28       Impact factor: 3.843

Review 4.  Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.

Authors:  Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás
Journal:  J Nutr Biochem       Date:  2018-04-19       Impact factor: 6.048

5.  Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease.

Authors:  Paula Scalzo; Arthur Kümmer; Thales Lage Bretas; Francisco Cardoso; Antônio Lúcio Teixeira
Journal:  J Neurol       Date:  2009-10-22       Impact factor: 4.849

Review 6.  Potential therapeutic uses of BDNF in neurological and psychiatric disorders.

Authors:  Alan H Nagahara; Mark H Tuszynski
Journal:  Nat Rev Drug Discov       Date:  2011-03       Impact factor: 84.694

7.  Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration.

Authors:  Yuen-Sum Lau; Gaurav Patki; Kaberi Das-Panja; Wei-Dong Le; S Omar Ahmad
Journal:  Eur J Neurosci       Date:  2011-03-07       Impact factor: 3.386

8.  BDNF in the Aged Brain: Translational Implications for Parkinson's Disease.

Authors:  N M Mercado; T J Collier; C E Sortwell; K Steece-Collier
Journal:  Austin Neurol Neurosci       Date:  2017-09-19

Review 9.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Altered transcription factor trafficking in oxidatively-stressed neuronal cells.

Authors:  Vivek P Patel; Donald B Defranco; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2012-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.